In the Phase I clinical study of ICT-107 in GBM, newly diagnosed patients who received the vaccine in addition to the standard of care of surgery, radiation and chemotherapy demonstrated a one year overall survival of 100 percent and a two year survival of 80 percent. This compares favorably with historical 61.1 percent one-year and 26.5 percent two-year survival based on the standard of care alone.

The company has recently presented updated results of its Phase I trial of ICT-107 in GBM that was initiated in May 2007. Median two-year survival of 80.2% looked amazing compared to historical 26.5% for standard of care. Median progression free survival of 16.9 months also looked good compared to historical 6.9 months on standard of care. 11 of the 16 patients continue to survive, 6 with no tumor re-growth. Three of these patients have been disease free for almost four years. Median overall survival has not been reached. No serious adverse events have been reported and minor side effects have been limited to fatigue, skin rash and pruritis.

These results also compare well against new treatments. Avastin plus SOC increased median two-year OS to 45% while the experimental candidate CDX-110 from Celldex (NASDAQ:CLDX) improved it to 50%.

The future looks good for ImmunoCellular Therapeutics. Interim data is not far off, expected in the second half of 2012. The results should solidify its position as one of the most promising cancer immunotherapy plays and significantly de-risk the asset. The company currently trades at about $2.00 with a market cap of under $60 million. On June 1, Zacks Investment Research placed an Outperform rating on the stock with a $7 price target

insider schreef:als dit geen goed nieuws meer is dan weet ik het ook niet meer ....

The company has recently presented updated results of its Phase I trial of ICT-107 in GBM that was initiated in May 2007. Median two-year survival of 80.2% looked amazing compared to historical 26.5% for standard of care. Median progression free survival of 16.9 months also looked good compared to historical 6.9 months on standard of care. 11 of the 16 patients continue to survive, 6 with no tumor re-growth. Three of these patients have been disease free for almost four years. Median overall survival has not been reached. No serious adverse events have been reported and minor side effects have been limited to fatigue, skin rash and pruritis.

These results also compare well against new treatments. Avastin plus SOC increased median two-year OS to 45% while the experimental candidate CDX-110 from Celldex (NASDAQ:CLDX) improved it to 50%.

The future looks good for ImmunoCellular Therapeutics. Interim data is not far off, expected in the second half of 2012. The results should solidify its position as one of the most promising cancer immunotherapy plays and significantly de-risk the asset. The company currently trades at about $2.00 with a market cap of under $60 million. On June 1, Zacks Investment Research placed an Outperform rating on the stock with a $7 price target

hier het volledige artikel :
http://www.proactiveinvestors.com/compa ... 15229.html" onclick="window.open(this.href);return false;

insider schreef:het antwoord is duidelijk : "neen" ! De prijs vertegenwoordigt nog NIKS. Indien de huidige testresultaten worden bevestigd in de 2e fase van de ontwikkeling, dan is the sky the limit voor IMUC. Stel u voor : een survival rate van MEER dan 80 % !!!!! Dit is fe-no-me-naal !!!

In the Phase I clinical study of ICT-107 in GBM, 16 newly diagnosed patients who received the vaccine in addition to standard of care of surgery, radiation and chemotherapy demonstrated a one year overall survival of 100 percent and a two year survival of 80 percent.

Given the potential of ICT-107 in the glioblastoma market, which is a multi-billion dollar market in itself, and the potential for Immunocellular to develop similar treatments for multiple indications, IMUC is a cancer immunotherapy company to keep on the radar. Should the ongoing Phase II trial results prove to be as encouraging as the Phase I data were, then it should be expected that IMUC will be trading for prices much closer to, or higher than, the $5 and $7 price targets that are out there at the current time.

The story can be accessed at http://newyork.cbslocal.com/category/vi ... mand-news/" onclick="window.open(this.href);return false; under Latest Videos by going to the bottom of the page and clicking on “Vaccine Could Kill Brain Tumors by Using Body’s…

insider schreef:http://newyork.cbslocal.com/category/vi ... mand-news/

indien de juiste video niet verschijnt tik je bij "search" het woord "vaccine" in en je krijgt het bericht over IMUC te zien !

The story can be accessed at http://newyork.cbslocal.com/category/vi ... mand-news/" onclick="window.open(this.href);return false; under Latest Videos by going to the bottom of the page and clicking on “Vaccine Could Kill Brain Tumors by Using Body’s…

insider schreef:de reden is eenvoudig ; het middel bewijst nu reeds dat het werkt en dit met een schitterend resultaat tot gevolg !